LMR Partners’s Corvus Pharmaceuticals CRVS Stock Holding History

LMR Partners’s Portfolio CRVS Stock Details CRVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-152,500	Closed	-$816K	–	1421
2024 Q4	$816K	Buy	+152,500	New	+$1.14M	0.01%	761

Other funds holding CRVS

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ASP

Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

FCMV

Foresite Capital Management VI Larkspur, California $643M AUM 343.43% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

LMR Partners's CRVS Position: Q2 2025 in Review

LMR Partners sold out of Corvus Pharmaceuticals (CRVS) in Q2 2025, closing a stake of 29,858 shares — an estimated $94.9K sold.

LMR Partners first reported a position in CRVS in Q3 2021 and held it in 8 quarters. The position peaked at $145K in Q3 2021. 92 funds tracked by Wall St. Rank hold CRVS as of Q2 2025.

LMR Partners reported no remaining Corvus Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
LMR Partners sold 29,858 Corvus Pharmaceuticals shares in Q2 2025, an estimated $94.9K.
LMR Partners first reported a position in Corvus Pharmaceuticals in Q3 2021 and held it in 8 quarters.
LMR Partners's Corvus Pharmaceuticals position peaked at $145K in Q3 2021.
92 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2025.

Based on LMR Partners's 13F filing for Q2 2025, filed 14 Aug 2025.